

(12) UK Patent Application (19) GB (11) 2 360 089 (13) A

(43) Date of A Publication 12.09.2001

(21) Application No 0005683.8

(22) Date of Filing 10.03.2000

(71) Applicant(s)
Universite de Geneve
(Incorporated in Switzerland)
Rue Général-Dufour 24, Case Postale, CH-1211,
GENEVA 4, Switzerland

(72) Inventor(s)
Jean-Charles Sanchez
Denis Francois Hochstasser

(74) Agent and/or Address for Service
Lucas & Co
135 Westhall Road, WARLINGHAM, Surrey, CR6 9HJ,
United Kingdom

(51) INT CL⁷
G01N 33/543, C07K 14/47 14/775, G01N 33/577 33/68

(52) UK CL (Edition S)
G1B BAE B103 B309 B403 B500


(56) Documents Cited
EP 0861900 A WO 98/45440 A WO 98/23962 A
Mol. Cell. Biochem.; Vol 198(1&2), pp 69-78 (1999). Pu
et al J. Neurochem.; Vol 66 (4), pp 1648-1656 (1996).
Myers-Payne et al

(58) Field of Search
UK CL (Edition R) G1B BAE
INT CL⁷ C07K 14/47 14/775, G01N 33/543 33/577
33/68
ONLINE: JAPIO, WPI, EPODOC, TXTE, MEDLINE,
EMBASE, SCISEARCH, BIOSIS, CAPLUS

(54) Abstract Title
Diagnostic assay for transmissible spongiform encephalopathies

(57) Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, especially CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using a specific antibody thereto. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried out.

GB 2 360 089 A



1/1

- 1 -

"DIAGNOSTIC ASSAY FOR TRANSMISSIBLE SPONGIFORM
ENCEPHALOPATHIES"

BACKGROUND OF THE INVENTION

Field of the invention

5 This invention is in the field of diagnostic assay
using a protein or an antibody thereto.

Description of the related art

 Transmissible spongiform encephalopathies (TSEs) are
neurodegenerative diseases of the central nervous system.
10 They can be transmitted, inherited or occur sporadically
and are observed in animals, e.g. as bovine spongiform
encephalopathy in cattle or scrapie in sheep, as well as
in humans as Creutzfeldt-Jakob disease (CJD), Gerstman
Sträussler Scheinker syndrome, Fatal Familial Insomnia or
15 Kuru. They have a long incubation period, leading to
ataxia, dementia, psychiatric disturbances and death.
Neuropathological changes include vacuolar degeneration
of brain tissue, astrogliosis and amyloid plaque
formation. The diseases are difficult to diagnose pre-
20 mortem.

 The cerebrospinal fluid (CSF) of CJD patients
displays two additional polypeptide by two-dimensional
polyacrylamide gel electrophoresis [Harrington, M.G. New
England Journal of Medicine 315, 279 (1986), Hsich, G.,
25 Kenney, K., Gibbs, C.J., Lee, K.H. & Harrington, M. B.
New England Journal of Medicine 335, 924 (1996).] The
function of these 14-3-3 polypeptides remain unclear in
TSE. They can be used in a pre-mortem test for CJD
diagnostic evaluation, but have low specificity.

30 Monoclonal antibodies to the abnormal form of prion
protein are available and can be used in an enzyme-linked
immunoassay, as described in PCT Specifications WO
98/23962 and 98/32710 and Schmerr, M.J., the Beckman

Coulter Pace Setter Newsletter 3(2),1-4 (June 1999), but these procedures have not yet been fully developed.

Development of new non-invasive blood CJD and BSE markers would help clinicians to establish early
5 diagnosis.

SUMMARY OF THE INVENTION

It has now surprisingly been found that two fatty acid binding proteins (FABP), known as heart (H-FABP) and brain (B-FABP), are markers for TSEs. Thus, a TSE or the
10 possibility thereof in a sample of body fluid taken from a patient suspected of suffering from the TSE, which comprises determining the concentration of heart or brain fatty acid binding protein (H-FABP or B-FABP) in the sample. the method is especially applicable to the
15 diagnosis of CJD in human patients.

Conveniently the method is carried out using an antibody to H-FABP or B-FABP, whereby the extent of the reaction between the antibody and the FABP in the sample is assayed and related to the concentration of FABP in
20 the sample. The concentration thus determined is used to make or assist in making a diagnosis.

The present invention enables an assay of high sensitivity, specificity and predictive accuracy for CJD to be carried out. "Sensitivity" is defined as the
25 percentage of true positives given by the assay on samples taken from patients in whom clinical examination has confirmed CJD. "Specificity" means the percentage of true negatives given by the assay on control samples, i.e. from patients in whom clinical examination has not revealed CJD. "Predictive accuracy" means the ratio of
30 true positives to total positives (true + false) expressed as a percentage.

H-FABP is a known marker of acute myocardial infarction (AMI), see Ishii, J. et al., "Serum

concentrations of myoglobin vs human heart-type cytoplasmic fatty-acid binding protein in early detection of acute myocardial infarction", *Clinical Chemistry* 1997;43 1372-1378. Therefore, in order to use an assay
5 for H-FABP for the diagnosis of CJD in humans to better advantage, it is desirable to perform another kind of assay for AMI (one in which the marker is not a FABP) in order to eliminate from the diagnosis for CJD those patients who are positive in the AMI assay.

10 Thus, in a particular embodiment, the invention provides a method which comprises determining the concentration of H-FABP in a first assay, as defined above, whereby a positive result indicates either a CJD or acute myocardial infarction, and which further
15 comprises carrying out a second diagnostic assay, for acute myocardial infarction (AMI) only, whereby a positive result in the H-FABP assay and a negative result in the assay for AMI indicates that the patient might be suffering from CJD. Assays using Troponin-I and Creatine
20 Kinase-MB (CK-MB) as early biochemical markers of acute myocardial infarction (AMI) are well known and suitable for the above purpose.

A similar H-FABP and also a brain-specific fatty acid binding protein (B-FABP) have been found in the
25 brain of mice, see Pu, L. et al., *Molecular and Cellular Biochemistry* 198, 69-78 (1999). Brain H-FABP (not to be confused with B-FABP) is believed to differ from heart H-FABP by a single amino acid substitution. However, B-FABP differs considerably. Sellner, P.A. et al., "
30 Development role of fatty acid binding proteins in mouse brain" *Dev. Brain Res.* 89, 33-46 (1995), estimated the DNA homology at 69%, while A. Schreiber et al., "Recombinant human heart-type fatty acid binding protein as standard in immunochemical assays", *Clin. Chem. Lab.*

Med. 36(5), 283-288 (1998), mention 64% amino acid sequence homology and that a monoclonal antibody to human H-FABP is cross-reactive with human B-FABP to the extent of only 1.7%.

5 Now that the present inventors have found that H-FABP is a marker for CJD, it is a very reasonable prediction that B-FABP will also be. Since B-FABP is specific to brain tissue and does not appear to react significantly with a monoclonal antibody to H-FABP, it
10 will not give positives for AMI, making a separate assay for AMI unnecessary.

BRIEF DESCRIPTION OF THE DRAWINGS

 The Figure is a graphic representation on the y-axis of H-FABP concentration represented by optical density
15 measurement at 405 nm, as determined by the method of the invention, for (a) a control group having neither CJD nor AMI (b) a group having AMI and (c) a group having CJD.

DESCRIPTION OF PREFERRED EMBODIMENTS

 For the method of assay, the sample can be taken
20 from any convenient body fluid of the subject. The method is considered applicable to all types of TSE, including those referred to above, and to any human or animal suffering therefrom. The marker, H-FABP or B-FABP, is preferably measured by an immunoassay, using a
25 specific antibody to H-FABP and measuring the extent of the antigen (H-FABP or B-FABP)/antibody interaction. For the diagnosis of human patients, the antibody is preferably anti-human H-FABP or B-FABP. Similarly, if the patient is an animal the antibody should be to the H-FABP
30 or B-FABP of the same animal variety, e.g. anti-bovine H-FABP or B-FABP if the patient is bovine. It may be a monoclonal antibody or an engineered antibody. Conveniently a mouse anti-human, anti-bovine etc. (depending on the animal from which the sample to be

tested has been derived) monoclonal antibody is used. Antibodies to H-FABP are known, e.g. 66E2 and 67D3 described by Roos, W. et al., "Monoclonal antibodies to human heart type fatty acid-binding protein", J. Immunol. Methods 183 149-153 (1995). Antibody 66E2 is commercially available. Also, the usual Köhler-Milstein method may be used to raise H-FABP or B-FABP antibodies. The source of protein for this purpose can be the naturally derived or recombinant DNA-prepared protein. Recombinant human H-FABP and B-FABP have been described by Schreiber, A. supra and Shimizu, F. et al., "Isolation and expression of a cDNA for human brain fatty acid binding protein (B-FABP)", Biochim Biophys. Acta 1354, 24-28 (1997), respectively. Less preferably, the antibody may be polyclonal.

Any known method of immunoassay may be used. A sandwich assay is preferred. In this method, a first antibody to the FABP is bound to the solid phase such as a well of a plastics microtitre plate, and incubated with the sample and with a labelled second antibody specific to the H-FABP or B-FABP to be detected. Alternatively, an antibody capture assay could be used here, the test sample is allowed to bind to a solid phase, and the anti-FABP antibody is then added and allowed to bind. After washing away unbound material, the presence or amount of antibody bound to the solid phase is determined using a labelled second antibody, anti- to the first.

In another embodiment, a competition assay could be performed between the sample and a labelled FABP or a peptide derived therefrom, these two antigens being in competition for a limited amount of anti-FABP antibody bound to a solid support. The labelled FABP or peptide could be pre-incubated with the antibody on the solid

phase, whereby the FABP in the sample displaces part of the FABP or peptide thereof bound to the antibody.

5 In yet another embodiment, the two antigens are allowed to compete in a single co-incubation with the antibody. After removal of unbound antigen from the support by washing, the amount of label attached to the support is determined and the amount of protein in the sample is measured by reference to standard titration curves established previously.

10 The label is preferably an enzyme. The substrate for the enzyme may be colour-forming, fluorescent or chemiluminescent.

15 It is highly preferable to use an amplified form of assay, whereby an enhanced "signal" is produced from a relatively low level of protein to be detected. One particular form of amplified immunoassay is enhanced chemiluminescent (ECL) assay. Here, the antibody is preferably labelled with horseradish peroxidase, which participates in a chemiluminescent reaction with luminol, 20 a peroxide substrate and a compound which enhances the intensity and duration of the emitted light, typically 4-iodophenol or 4-hydroxycinnamic acid.

25 Another preferred form of amplified immunoassay is immuno-PCR. In this technique, the antibody is covalently linked to a molecule of arbitrary DNA comprising PCR primers, whereby the DNA with the antibody attached to it is amplified by the polymerase chain reaction. See Hendrickson, E.R. et al., Nucleic Acids Research 23, 522-529 (1995) or Sano, T. et al., in 30 "Molecular Biology and Biotechnology" ed. Robert A. Meyers, VCH Publishers, Inc. (1995), pages 458 - 460. The signal is read out as before.

In a particularly preferred procedure, an enzyme-linked immunosorbent assay (ELISA) was developed to

detect H-FABP in serum. Since H-FABP is a marker for AMI as well, Troponin-I or CK-MB levels were assayed in order to exclude any heart damage. As described in the Example, these assays were assessed in serial plasma and
5 CSF samples, from patients lacking AMI and CJD, patients with AMI, patients with dementia and patients with confirmed CJD through autopsy. The sensitivity, specificity and predictive accuracy for H-FABP in CJD above a suitable cut-off level were all 100%. Thus, H-
10 FABP detection combined with the Troponin-I or CK-MB assay provides a useful serum marker of CJD diagnosis or brain damage.

The use of a rapid microparticle-enhanced turbidimetric immunoassay, developed for H-FABP in the
15 case of AMI, Robers, M. et al., "Development of a rapid microparticle-enhanced turbidimetric immunoassay for plasma fatty acid-binding protein, an early marker of acute myocardial infarction", Clin. Chem. 44, 1564-1567 (1998), should drastically decrease the time of the
20 assay. Thus, the full automation in a widely used clinical chemistry analyser such as the COBAS™ MIRA Plus system from Hoffmann-La Roche or the AxSYM™ system from Abbott laboratories should be possible and applied for routine clinical diagnosis of CJD.

25 The H-FABP or B-FABP can be measured by other means than immunoassay. For example, the sample can be subjected to 1 or 2-DE gel electrophoresis and the amount of the FABP estimated by densitometric scanning of the gel or of a blot therefrom.

30 The assay of the invention can be used together with one or more other pre-mortem assays for the TSE, including specifically those assays described above. Such combined procedures are particularly useful in diagnosing BSE in cattle.

The following Example illustrates the invention.

EXAMPLE

Materials And Methods

Patients

5 The study population consisted of 3 age-and-gender
matched control patients (Control group), 3 confirmed AMI
patients (AMI group), 3 confirmed dementia patients
(dementia group) and 3 confirmed CJD patients (CJD
10 group). The Control group included 2 men, mean age 66,
range 46-86 years, and 1 woman, age 63 years. The AMI
group included 2 men, mean age 65, range 40-90 years, and
1 woman, age 72 years. The dementia group included 2 men,
mean age 65, range 43-87 years, and 1 women, age 64
15 years. The CJD group included 2 men, mean age 68, range
62-74 years, and 1 woman, age 65. Blood and CSF samples
were collected for each patient of the CJD. Blood samples
were collected in dry heparin-containing tubes. After
centrifugation at 1500g for 15min at 4°C, tubes were
20 stored at -20°C until analysis. Patients from the CJD
group underwent serial clinical evaluations by
neurologists in order to confirm CJD diagnosis. Patients
from the AMI group were admitted to the hospital with a
confirmed AMI (Troponin-I concentration >2ng/ml). A
clinical evaluation was performed on all the patients
25 from the control group to exclude CJD and AMI.

Measurement of brain and heart H-FABP

H-FABP levels were measured in plasma by a sandwich
ELISA. A 96-well polystyrene microplate (NUNC) was coated
with 100µl/well goat anti human-FABP, detecting all
30 isoforms (Spectral Diagnosis HC, Ontario, USA), 20.4ng/ml
in carbonate buffer 0.1M pH 9.6, overnight at 4°C. The
plate was automatically washed with PBS (15mM Na₂PO₄-120mM
NaCl-2.7mM KCl pH 7.4, Sigma) on a BioRad NOVAPATH™
washer. Every washing step was performed with fresh PBS.

Non-specific binding sites were blocked with 200µl/well 2% casein in carbonate buffer for 2h at 37°C. After the washing step, the samples were pipetted in duplicate at 100µl/well. The plate was incubated 2h at 37°C. After the washing step, 100µl/well of mouse anti-human Heart FABP (clone 66E2, HyCult Biotechnology BV, Uden, Netherlands), 0.3ng/ml in PBS-1%BSA, were incubated for 1h at room temperature (R.T) with shaking. After the washing step, 100µl/well of phosphatase-labelled anti-mouse immunoglobulin (Dako, Denmark), 15ng/ml in PBS, were incubated 1h 30min at R.T. with shaking. After the washing step, 50µl/well of phosphatase substrate, 1.5mg/ml para-nitrophenylphosphate in diethanolamine was added and the samples were then incubated for 30min. The reaction was stopped with 100µl/well 1M NaOH. Colour development was measured with a microplate reader at a wavelength of 405nm.

CK-MB and Troponin-I measurement

AMI was diagnosed by clinical evaluation and Troponin-I and CK-MB measurements. Samples were centrifuged at 1500g for 15min, and stored at -20°C. Serum CK-MB and Troponin-I levels were determined using a fluorescent microparticle enzyme immunoassay (MEIA) with an automated chemical analyser AxSYM™ system (Abbott Laboratories, Abbott Park, IL, USA). The rate of formation of fluorescent products was directly proportional to the amount of Troponin-I in the sample. The detection limit for Troponin-I was 0.3pg/l. CK-MB measurement is proportional to the amount of fluorescent probes and the detection limit was 0.7pg/l.

Statistical analysis

H-FABP levels were expressed in optical densitometry (OD) values either as mean \pm SD or as median and inter-quartile range. Troponin-I and CK-MB levels were

expressed in concentration units (ng/ml). The non-parametric Mann-Whitney U-test and Kruskal-Wallis H-test were used to compare in plasma H-FABP, Troponin-I and CK-MB concentrations between groups. PRISM™ software was used to elaborate box/whisker and scatter plots. The 95% confidence intervals (CI) and Receiver Operating Characteristic (ROC) curves, defined by Analyse-it™ software for Microsoft EXCEL™, were used to assess the discriminatory time point of the indicators. See Murphy, J.M. et al., "Performance of screening and diagnostic tests", Arch. Gen. Psychiatry 44, 550-555 (1987).

$P < 0.05$ was considered statistically significant.

Results

Clinical characteristics

Patients from the CJD group were given a complete clinical evaluation. CJD was finally diagnosed with the help of brain immuno-histology after autopsy. Patients from the Control group were admitted to hospital and CJD and AMI were excluded by clinical evaluation.

Patients from the AMI group were admitted to the hospital with confirmed AMI with high Troponin-I levels ($>2\text{ng/ml}$).

Assay results are shown in Table 1 below.

Assay type	Control Group plasma	AMI Group plasma	Dementia Group CSF	CJD Group plasma	CJD Group CSF
H-FABP median (25-75%) OD, 405 nm	0.25 (0.23-0.27)	2.89 (2.70-3.0)	0.20 (0.16-0.31)	0.79 (0.74-0.86)	0.46 (0.38-0.54)
Troponin-I median (25-75%) IU ng/ml	0 (0.0-0.0)	50 (50-359)	0 (0.0-0.2)	0 (0.0-0.2)	0 (0.0-0.2)

H-FABP plasma levels (OD measurement) in the AMI group were significantly higher than the respective level in the Control group (Table 2). The AMI group had a H-FABP median level (range 25-75%) of 2.89 (2.70-3.0) while the Control group had a level of 0.25 (0.23-0.27). The H-FABP plasma level in the CJD group was between the slopes of the AMI and the Control groups. H-FABP median (range 25-75%) level in the plasma CJD group was 0.79 (0.74-0.86). The sensitivity, specificity, and predictive accuracy of H-FABP levels beyond the cut off value of 0.30 were 100%, 100% and 100% respectively. To confirm differences in H-FABP concentrations between AMI and Control groups, Troponin-I was assayed. In addition, in order to discriminate AMI and CJD, they were also assayed on CJD samples. The Troponin-I concentration was measured in each group. Troponin-I concentration in the AMI group was significantly ($p > 0.01$) higher than in the Control group.

Discussion

The above results indicate that H-FABP is a potential marker for CJD diagnosis. Since H-FABP was presented as a marker of acute myocardial infarction a few years ago, CJD and AMI had to be discriminated by another AMI biochemical marker such as Troponin-I or CK-MB. After the discrimination of AMI for CJD patient, the serum as well as the CSF H-FABP concentration could be used as a specific marker of CJD.

In the present study, H-FABP assay allowed a sensitivity, a specificity and a predictive accuracy (OD response > 0.30) of 100%. These values were significantly higher than those of 14-3-3 protein for detection of CJD as the three dementia patients were positive after immunoblotting detection. The specificity of 14-3-3 is

not limited to CJD but includes also Alzheimer's dementia, cerebral complications from head injury and some other forms of dementia.

5 Acute myocardial infarction is diagnosed with the help of biochemical marker assays such as cardiac Troponin-I, Creatine-Kinase MB, myoglobin and recently H-FABP assay. The H-FABP level for CJD could interfere with AMI and discrimination between AMI and CJD was made with the use of other AMI markers.

10

* * * * *

Each of the above cited publications is herein incorporated by reference to the extent to which it is relied on herein.

15 The following claims define some important embodiments of the invention, but should not be construed as detracting from the generality of the concepts hereinbefore set forth.

CLAIMS

1. A method of diagnostic assay for a transmissible spongiform encephalopathy (TSE) or the possibility thereof in a sample of body fluid taken from a patient suspected of suffering from the TSE, which comprises determining the concentration of heart or brain fatty acid binding protein (H-FABP or B-FABP) in the sample.
2. A method according to Claim 1, wherein the subject is a human and the concentration of H-FABP is determined in a first assay, whereby a positive result indicates either a CJD or acute myocardial infarction, and which further comprises carrying out a second diagnostic assay, for acute myocardial infarction (AMI) only, whereby a positive result in the H-FABP assay and a negative result in the assay for AMI indicates that the patient is or might be suffering from a CJD.
3. A method according to Claim 2, wherein the assay for AMI comprises determining the concentration of troponin-1 or creatine kinase MB in plasma.
4. A method according to Claim 1, 2 or 3, wherein an antibody to H-FABP is used in the assay for H-FABP.
5. A method according to Claim 4, wherein the subject is a human patient and a mouse anti-human FABP monoclonal antibody is used.
6. A method according to any Claim 4 or 5, wherein the assay for H-FABP comprises a sandwich ELISA.
7. A method according to Claim 1, wherein B-FABP or an antibody thereto is used without any assay for AMI in combination therewith.
8. A method according to any preceding Claim, wherein the H-FABP or B-FABP assay is carried out on a blood or serum sample.



INVESTOR IN PEOPLE

Application No: GB 0005683.8
Claims searched: All

Examiner: Dr Rowena Johnson
Date of search: 10 August 2000

Patents Act 1977
Search Report under Section 17

Databases searched:

UK Patent Office collections, including GB, EP, WO & US patent specifications, in:
UK Cl (Ed.R): G1B (BAE)
Int Cl (Ed.7): G01N 33/543, 33/577, 33/68; C07K 14/47, 14/775
Other: ONLINE: WPI, JAPIO, EPODOC, TXTE, MEDLINE, EMBASE, SCISEARCH, BIOSIS, CAPLUS

Documents considered to be relevant:

Category	Identity of document and relevant passage	Relevant to claims
A	EP0861900A (ERZIEHUNGSDIREKTION OF THE CANTON ZURICH) See especially examples	
A	WO98/45440A (INCYTE PHARMACEUTICALS INC) See especially page 20 line 24-page 21 line 14	
A	WO98/23962A (ELECTROPHORETICS INTERNATIONAL PLC) See especially example	
A	<i>Mol. Cell. Biochem.</i> ; Vol 198 (1&2), pp 69-78 (1999). Pu <i>et al.</i> See especially discussion	
A	<i>J. Neurochem.</i> ; Vol 66 (4), pp 1648-1656 (1996). Myers-Payne <i>et al.</i> See especially discussion	

X	Document indicating lack of novelty or inventive step	A	Document indicating technological background and/or state of the art
Y	Document indicating lack of inventive step if combined with one or more other documents of same category.	P	Document published on or after the declared priority date but before the filing date of this invention.
&	Member of the same patent family	E	Patent document published on or after, but with priority date earlier than, the filing date of this application.